ARK Genomic Revolution ETF
ARKG
- $51.65
- 2.93
- 6.01%
ARK Genomic Revolution ETF ARKG Strategy
The investment seeks long-term growth of capital.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
Young & Invested: This Aussie ETF has outperformed the ASX 200 for over a decade
What happens when you build an index around fundamentals instead of share price?
etfs
Future Focus: The new Aussie portfolio
The State of the Australian Investor reveals how Aussies are building their portfolios.
etfs
Young & Invested: Investors are flocking to this ETF. But are they making the right choice?
Higher yields and an increasingly concentrated share market are pushing investors back towards fixed income. The question is whether they’re taking the correct approach.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,887.14 | 39.82 | 0.51% |
| DAX 40 | 25,590.77 | 179.93 | 0.71% |
| Dow JONES (US) | 52,377.57 | 15.99 | 0.03% |
| FTSE 100 | 10,686.54 | 80.79 | -0.75% |
| HKSE | 23,061.04 | 19.72 | 0.09% |
| NASDAQ | 26,477.81 | 308.43 | 1.18% |
| Nikkei 225 | 64,115.56 | 847.19 | 1.34% |
| NZX 50 Index | 13,691.33 | 11.06 | 0.08% |
| S&P 500 | 7,722.60 | 45.83 | 0.60% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,669.26 | 20.96 | 0.57% |